AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31491384
Drug: Broad-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotics treatment
Trial: 23633090
Drug: Treatment-as-usual plus
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual plus take-home emergency naloxone
Trial: 22435280
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg single IV bolus (Precalculated group, PG)
Trial: 22435280
Drug: Titration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration of Propofol (Titration group, TG)
Trial: 15606472
Drug: Dorzolamide/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide/timolol fixed combination (D/T)
Trial: 11528357
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg norethindrone acetate (NA)/5 microg ethinyl estradiol (EE)
Trial: 11528357
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg norethindrone acetate (NA)/5 microg ethinyl estradiol (EE)
Trial: 11528357
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg norethindrone acetate (NA)/10 microg ethinyl estradiol (EE)
Trial: 11528357
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogens (CEE)/2.5 mg medroxyprogesterone acetate (MPA)
Trial: 7705552
Drug: sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 2 g b.d.
Trial: 3300310
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of norfloxacin (600 mg twice daily)
Trial: 3300310
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of norfloxacin (800 mg)
Trial: 3300310
Drug: Single-dose ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ampicillin (3.5 g)/probenecid (1.0 g)
Trial: 1062553
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B toothbrush
Trial: 30047786
Drug: Escitalopram (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10‐20 mg)
Trial: 21716274
Drug: Clopidogrel regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel regimen of 300 mg loading dose (LD) and 75 mg/day maintenance dose (MD) for 4 days
Trial: 21716274
Drug: Clopidogrel regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel regimen of 600 mg LD and 150 mg/day MD
Trial: 21716274
Drug: Clopidogrel regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel regimen of 75 mg/day MD
Trial: 21716274
Drug: Clopidogrel regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel regimen of 150 mg/day MD
Trial: 19648146
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 220 mg and 150 mg
Trial: 16729745
Drug: Continuous low-volume
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low-volume infusion (10 cc of dye infused over 2.5 hours)
Trial: 16729745
Drug: Intermittent high-volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-volume bolus infusion (10 cc bolus of dye)
Trial: 9243208
Drug: Cyclic conjugated
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic conjugated oestrogens 0.3 mg/day
Trial: 9243208
Drug: Cyclic conjugated
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic conjugated oestrogens 0.625 mg/day
Trial: 9243208
Drug: Cyclic conjugated
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic conjugated oestrogens 1.25 mg/day
Trial: 30403495
Drug: Webdia app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Webdia app intervention for 3 months with monthly feedback and adaptation of treatment
Trial: 18317243
Drug: Triflusal (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal (900 mg for 18 months)
Trial: 16215013
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zinc/d in cherry syrup
Trial: 16215013
Drug: Cherry syrup
RxNorm normalized name: CHERRY SYRUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cherry syrup alone (placebo)
Trial: 10215647
Drug: MK‐966 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐966 (50 mg every day)
Trial: 1706607
Drug: HIV-1 recombinant
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 recombinant gp160 vaccine (40 or 80 micrograms)
Trial: 1706607
Drug: HIV-1 recombinant
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 recombinant gp160 vaccine (fourth immunization)
Trial: 1706607
Drug: HIV-1 recombinant
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 recombinant gp160 vaccine
Trial: 30064953
Drug: ACCU-CHEK Inform
RxNorm normalized name: Accu-Chek Inform II System Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACCU-CHEK Inform II displaying '32 mg/dL' reading
Trial: 27194176
Drug: FOLFOX (fluorouracil-oxaliplatin-folinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX (fluorouracil-oxaliplatin-folinic acid) combined with concurrent radiotherapy (41.4 Grays)
Trial: 27194176
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and paclitaxel combined with concurrent radiotherapy (41.4 Grays)
Trial: 24227768
Drug: Buprenorphine (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (32 mg/day i.m.)
Trial: 24227768
Drug: Morphine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (120 mg/day i.m.)
Trial: 22831286
Drug: Fruit and
RxNorm normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit and vegetable puree-based drinks (FVPD) 200 mL daily for 6 weeks
Trial: 12174518
Drug: Antiplatelet drug
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drug triflusal (600 mg)
Trial: 12174518
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with anticoagulation (mean INR of 1.85)
Trial: 12174518
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with anticoagulation (mean INR of 2.15)
Trial: 7793997
Drug: AO-90 (500-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO-90 (500-750 ml/day)
Trial: 7793997
Drug: Commercial amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial amino acid solution (600-800 ml/day)
Trial: 393386
Drug: DTIC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC at a dose of 200 mg/m2 iv on Days 1‐5 and cis‐dichlorodiammine‐platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks (group A)
Trial: 393386
Drug: DTIC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC at a dose of 200 mg/m2 iv on Days 1‐5 and cis‐dichlorodiammine‐platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks, plus procarbazine at a dose of 75 mg/m2 orally daily on Days 1‐8 and vincristine at a dose of 1.4 mg/m2 iv on Day 1 (group B)
Trial: 30060681
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (CSI) alone
Trial: 30060681
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (CSI) with 3 weeks of immobilization
Trial: 31262544
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hydrocortisone orally
Trial: 25694068
Drug: Milled flaxseed
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milled flaxseed (30 g/day)
Trial: 25694068
Drug: Milled flaxseed
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milled flaxseed (30 g/day) + cholesterol-lowering medications (CLM)
Trial: 25694068
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 g whole wheat) + cholesterol-lowering medications (CLM)
Trial: 21689900
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 μg
Trial: 18925978
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) B12 replacement therapy
Trial: 18925978
Drug: Normal serum
RxNorm normalized name: Albumin, Normal Serum, Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal serum B12 levels (>300 pg/mL)
Trial: 9523927
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (2 mg, 4 mL)
Trial: 9523927
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 mL of nebulized normal saline)
Trial: 2039811
Drug: 49.2 mg
RxNorm normalized name: fusidate 49.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 49.2 mg pseudoephedrine (ACTIFED)
Trial: 2039811
Drug: 1.51 L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.51 L mineral water
Trial: 30663520
Drug: Subanaesthetic intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanaesthetic intravenous ketamine infusion
Trial: 29273594
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.8 mg combined with enalapril 10 mg
Trial: 26590016
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of normal saline injected into the knee joint of the experimental group.
Trial: 22898278
Drug: Specific sublingual
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific sublingual immunotherapy with dermatophagoides farinae drops
Trial: 22898278
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment alone (Control)
Trial: 20724562
Drug: L-arginine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (6 g in 500 ml beverage)
Trial: 18424200
Drug: 6% Hydroxyethylstarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% Hydroxyethylstarch 130/0.4 (median of 750 ml administered)
Trial: 12540643
Drug: Nimodipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (60 mg orally every 4 hours)
Trial: 12540643
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (intravenous according to institutional protocol)
Trial: 10653212
Drug: biperiden (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biperiden (4 mg)
Trial: 10653212
Drug: trihexyphenidyl (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trihexyphenidyl (5 mg)
Trial: 8447161
Drug: Cold-adapted live
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted live attenuated vaccine (two doses)
Trial: 8447161
Drug: Whole-virus inactivated
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus inactivated vaccine (one dose)
Trial: 31268610
Drug: Alteplase 2
RxNorm normalized name: alteplase 20 mg INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 2 mg
Trial: 31268610
Drug: Alteplase 1
RxNorm normalized name: alteplase 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 1 mg
Trial: 26833336
Drug: Ad26.EnvA and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.EnvA and Ad35.Env (both administered at a dose of 5 × 10^10 viral particles)
Trial: 24743802
Drug: Alprazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.25 mg)
Trial: 20975066
Drug: Sequential high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential high-dose chemotherapy (SHDCT) before myeloablative therapy
Trial: 20975066
Drug: Standard arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard arm (A) with myeloablative therapy with carmustine, BEAM followed by PBSCT
Trial: 18925347
Drug: Treatment-naive group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-naive group
Trial: 18925347
Drug: One to
RxNorm normalized name: One Touch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One to two prior treatments group
Trial: 18925347
Drug: Three or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or more prior treatments group
Trial: 15847747
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.2 mg daily for 3 months
Trial: 15847747
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5.2 mg daily for 3 months
Trial: 12059949
Drug: Ritonavir/Indinavir at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir/Indinavir at 400/400 mg BID in combination with two NRTIs (ZDV/3TC, d4T/3TC, or d4T/ddI)
Trial: 12059949
Drug: Ritonavir/Indinavir at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir/Indinavir at 400/400 mg BID in combination with two NRTIs
Trial: 1756263
Drug: Postoperative locoregional
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative locoregional and pelvic radiotherapy (RX) and Poly(A).Poly(U) (AU), 60 mg IV once a week for 6 weeks
Trial: 1756263
Drug: CMF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (cyclophosphamide 100 mg/sqm P.O. on days 1‐14, methotrexate 40 mg/sqm IV on day 1 and 8, fluorouracil 600 mg/sqm IV on day 1 and 8; monthly cycle, for 6 months)
Trial: 6802412
Drug: Three-day course
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day course of amoxycillin (25 mg/kg daily)
Trial: 6802412
Drug: Ten-day course
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten-day course of amoxycillin (25 mg/kg daily)
Trial: 17537209
Drug: Defibrillator implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrillator implant
Trial: 15530197
Drug: Nursing session
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing session with five symposia and short oral presentations.
Trial: 11474345
Drug: C (5
RxNorm normalized name: ferric (59Fe) citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (5 mg x kg(‐1))
Trial: 11474345
Drug: E (1
RxNorm normalized name: methionine (11C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E (1 mg x kg(‐1))
Trial: 10921014
Drug: Intraperitoneal perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal perfusion chemotherapy (IPPC) with 1 g 5-Fu and 10 mg MMC in warm sterile water, once per day for 6 days.
Trial: 10921014
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 1 g 5-Fu and 8 mg MMC, once per day for 6 days (Control group).
Trial: 7977595
Drug: Povidone-iodine 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine 2.5% ophthalmic solution
Trial: 7977595
Drug: Silver nitrate
RxNorm normalized name: Silver Nitrate
DrugBank: Silver (DB12965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silver nitrate 1% ophthalmic solution
Trial: 7977595
Drug: Erythromycin 0.5%
RxNorm normalized name: ERYTHROMYCIN 0.5% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 0.5% ointment
Trial: 2596940
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg/d) plus potassium supplement (20 mmol/d)
Trial: 2596940
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg/d) plus potassium supplement (40 mmol/d)
Trial: 2596940
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg/d) with triamterene (75 mg/d)
Trial: 31345163
Drug: Curcumin 1500
RxNorm normalized name: Nature's Truth Turmeric Curcumin 1500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 1500 mg
Trial: 24453924
Drug: Sulphurous thermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphurous thermal water inhalation
Trial: 21960699
Drug: Nebulized levalbuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized levalbuterol 0.63 mg
Trial: 19120892
Drug: rabeprazole, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole, amoxicillin, and GAT for 7 days (RAG)
Trial: 19120892
Drug: rabeprazole and
RxNorm normalized name: Dexrabeprazole and domperidone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole and amoxicillin (RA)
Trial: 16646120
Drug: Intensive mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive mental activity (daily memorization of prose passages and demanding mental arithmetic) for 2 weeks
Trial: 2003591
Drug: Naloxone (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (1.2 mg iv bolus)
Trial: 7025090
Drug: Methylglucamine metrizoate
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylglucamine metrizoate (Isopaque Cerebral, 280 mg I/mI)
Trial: 7025090
Drug: Metrizamide (Amipaque,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrizamide (Amipaque, 280 mg I/mI)
Trial: 29187584
Drug: BsAb-5 (bispecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BsAb-5 (bispecific antibody targeting c-MET and CTLA-4)
Trial: 27563831
Drug: Tailored exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored exercise therapy (20-week individualized, comorbidity-adapted exercise program consisting of aerobic and strength training and training of daily activities)
Trial: 24209639
Drug: Fasting for
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting for 2 hours (F2) with 200 ml of clear liquids ingested 2 hours before the procedure
Trial: 9848065
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid therapy (short-time)
Trial: 9848065
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid therapy (long-time)
Trial: 9848065
Drug: Systemic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroid therapy (bolus group)
Trial: 9848065
Drug: Systemic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroid therapy (tapering group)
Trial: 2576886
Drug: Somatostatin (SMS)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SMS) administered epidurally
Trial: 2576886
Drug: Somatostatin (SMS)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SMS) administered epidurally in group A (procto-anal)
Trial: 2576886
Drug: Somatostatin (SMS)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SMS) administered epidurally in group B (inguino-crural)
Trial: 31120614
Drug: Continuous ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ropivacaine (0.2% at 4‐6 ml/h)
Trial: 28012403
Drug: Basal-bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus therapy based on analog insulin (detemir/aspart)
Trial: 28012403
Drug: Basal-bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus therapy based on human insulin (NPH/regular)
Trial: 28012403
Drug: Analog insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analog insulin treatment
Trial: 28012403
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin treatment
Trial: 28012403
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (analog and human insulin)
Trial: 26046455
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% with fentanyl 5 μg/mL
Trial: 26046455
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% with fentanyl 5 μg/mL and epinephrine 5 μg/mL